Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS ...
AbbVie (NYSE:ABBV) Expands SKYRIZI Availability In Canada For Ulcerative Colitis Treatment
AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...
AbbVie (NYSE:ABBV) Shares Up 0.6% Following Analyst Upgrade
Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0.6% on Wednesday after Wells Fargo & Company raised their price target on the stock from $210.00 to $240.00. Wells Fargo & Company ...
AbbVie price target raised to $223 from $200 at BofA
BofA raised the firm’s price target on AbbVie (ABBV) to $223 from $200 and keeps a Neutral rating on the shares after the company and Gubra ...
Fierce Biotech3d
AbbVie pays Gubra $350M to make late play for obesity space
AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...
AbbVie Inc. (ABBV) TD Cowen 45th Annual Health Care Conference (Transcript)
AbbVie Inc. ( NYSE: ABBV) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R. Stewart - Executive ...
Wells Fargo Keeps Their Buy Rating on AbbVie (ABBV)
In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...
Yahoo Finance3d
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
The latest trading session saw AbbVie (ABBV) ending at $211.48, denoting a +1.17% adjustment from its last day's close. This change outpaced the S&P 500's 1.76% loss on the day. At the same time ...
BioSpace1d
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...